The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin

P Colombatto ,M Sarracino,V Romagnoli ,P.l Almasio ,A Muzzi ,Vincenzo Barnaba ,Mike Houghton ,Salvatore Madonia ,Domenico Rosa ,Antonio Ascione ,M.r Brunetto ,Silvia Fargion ,Anna Maria Maina ,Rino Rappuoli ,Antonio Craxı̀ ,Maria Grazia Rumi ,Silvia Montigiani ,Massimo Colombo ,Mario U Mondelli ,Sergio Abrignani ,Giovambattista Pinzello ,Fb Bianchi ,F Bonino

doi:10.1016/j.dld.2008.12.041

The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin

P Colombatto , M Sarracino + Show 21 more

https://doi.org/10.1016/j.dld.2008.12.041

Copy DOI

Journal: Digestive and Liver Disease

Publication Date: Mar 1, 2009

Affiliation: Roche (Italy), Epiphany Biosciences (United States), Novartis (Italy), Istituti di Ricovero e Cura a Carattere Scientifico, Istituto Nazionale Genetica Molecolare

#Phase Viral Decline #Viral Decline + Show 1 more

Abstract
Full-Text
Similar Papers

Abstract

The candidate HCV E1E2MF59 vaccine enhances 2nd phase viral decline in responders to PEG-IFN/ribavirin

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title

Journal

Date

Author

View more papers

More From: Digestive and Liver Disease

Paper Title

Journal

Date

Author

View more papers

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.